Represented Oklahoma Medical Research Foundation (OMRF) in a suit against Eli Lilly in the Western District of Oklahoma. OMRF alleged patent infringement and breach of a license agreement in connection with Eli Lilly's sales of Xigris, the first FDA-approved drug to treat severe sepsis. The suit settled on the eve of trial after more than 60 depositions, production of more than one million pages of documents by Eli Lilly, and a Markman hearing resulting in a claim construction favorable to our client.

Oklahoma Med. Research Found. v. Eli Lilly & Co., No. 01-0456 (W.D. Okla. filed Mar. 15, 2001).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Revolving credit facility for global manufacturer
Representation of publicly held leading global manufacturer of flooring products, as borrower, in connection with $100 million syndicated senior more
Catastrophic injury services for burn injury from industrial boiler explosion
Represented a man injured when an industrial plant boiler exploded causing superheated steam to escape.  The case settled through mediation. more
Biopolymer Engineering Inc. v. Immunocorp
The firm served as lead counsel for Biotec Pharmacon, ASA, a Norwegian pharmaceutical company, in patent infringement litigation initiated by more
Public procurement for Westinghouse Rail Systems Ltd.
Represented Westinghouse Rail Systems Ltd., a Swedish rail company and an international contractor, in a dispute regarding the procurement of a rail more